ROCKVILLE, MD – As the landscape of precision medicine evolves with unprecedented speed, the American Society of Human Genetics (ASHG) continues to serve as the global vanguard for the field. On September 24, 2026, the Society officially unveiled the recipients of its prestigious 2026 Publication Awards. This annual recognition honors the intellectual curiosity, technical rigor, and groundbreaking contributions of the next generation of scientists—trainees and early-career investigators whose work is redefining our understanding of the human genome.
The awards, distributed across two of the field’s most influential journals—The American Journal of Human Genetics (AJHG) and Human Genetics and Genomics Advances (HGG Advances)—celebrate research that pushes the boundaries of genetic discovery. These findings not only solve complex biological puzzles but also pave the way for more accurate clinical diagnoses and personalized therapeutic interventions.
The honorees are scheduled to be formally recognized during a high-profile awards ceremony at the 2026 ASHG Annual Meeting, set to take place in Montréal on October 22.
Main Facts: A New Era of Genomic Insight
The 2026 ASHG Publication Awards highlight four distinct research projects that reflect the diversity and complexity of modern genetics. From the application of advanced artificial intelligence in polygenic risk scoring to the meticulous functional characterization of rare, disease-causing mutations, the selected papers represent the pinnacle of current academic inquiry.
The awards are bifurcated into two categories: the AJHG Award for Outstanding Trainee Publication, which recognizes those currently in the midst of their doctoral or postdoctoral training, and the HGG Advances Early Career Investigator Award, which spotlights scientists who have recently transitioned into independent research roles.
The winners of the 2026 awards are:
- Nikolas Baya, PhD (Center for Genomic Medicine at Massachusetts General Hospital/Broad Institute of MIT and Harvard)
- Kathryn A. Lawrence, BS (Stanford University)
- Quan Sun, PhD (Children’s Hospital of Philadelphia/University of Pennsylvania)
- Cindy A. Thomas-Charles, PhD (University of Hartford)
Chronology: The Road to Scientific Excellence
The recognition of these scholars follows a rigorous, year-long peer-review process. The editorial boards of AJHG and HGG Advances systematically evaluate thousands of submissions, looking for papers that demonstrate not only technical brilliance but also the potential for long-term impact on the field.
- January – March 2026: Editorial boards begin the preliminary selection process, identifying top-tier manuscripts published in the preceding 12 months.
- April – June 2026: Shortlisted candidates undergo an intensive review by a panel of subject-matter experts, focusing on methodology, originality, and the robustness of the data presented.
- July – August 2026: The final selection committee convenes to determine the winners, ensuring a balance across sub-disciplines, including bioinformatics, clinical genetics, and molecular biology.
- September 24, 2026: The official public announcement is issued from ASHG headquarters in Rockville, Maryland, signaling the start of the lead-up to the October ceremony in Montréal.
Supporting Data: Innovations in Methodology and Discovery
The research recognized this year is characterized by a shift toward more sophisticated computational models and a deeper functional understanding of genetic variants.
AJHG Award for Outstanding Trainee Publication
Nikolas Baya’s work addresses one of the most persistent challenges in human genetics: the discrepancy between polygenic expectation and observed phenotypic outcomes. In his paper, “Individuals who deviate from polygenic expectation are enriched for damaging variants in genes linked to rare disease,” Baya provides a framework for understanding why certain individuals do not fit the standard models of polygenic risk. His findings suggest that "outlier" individuals often harbor rare, highly damaging mutations that standard polygenic scores fail to capture, highlighting a vital intersection between common and rare disease genetics.
Kathryn A. Lawrence, meanwhile, challenges the industry standard in her research, “Focus on single-gene effects limits discovery and interpretation of complex-trait-associated variants.” Lawrence argues that by focusing too heavily on individual genes, researchers are effectively missing the "forest for the trees." Her analysis demonstrates that complex traits are governed by interconnected networks of variants, and by broadening the analytical lens, researchers can unlock new pathways for drug discovery and patient stratification.
HGG Advances Early Career Investigator Award
In the realm of predictive analytics, Dr. Quan Sun has made a significant impact with his paper, “Variational autoencoder-based model improves polygenic prediction in blood cell traits.” By utilizing variational autoencoders—a type of generative artificial intelligence—Sun has developed a model that significantly improves the predictive power of polygenic scores. This leap in computational biology allows for more precise forecasting of blood-related phenotypes, a cornerstone of clinical diagnostic research.
Dr. Cindy A. Thomas-Charles brings a focus on functional validation with her study, “Investigating and correcting a rare pathogenic mutation in GDF11.” Her research moves beyond the identification of a variant to the functional correction of it. By focusing on the GDF11 gene, she provides a roadmap for how researchers can translate genotype-phenotype associations into actual therapeutic strategies, demonstrating the practical application of genomic editing technologies in a laboratory setting.
Official Responses and Society Perspective
The American Society of Human Genetics has long maintained that its strength lies in its ability to foster and elevate the voices of its members. Evelyn Mantegani, the primary media contact for the Society, noted that this year’s selection process was particularly competitive due to the sheer volume of high-quality research submitted to the journals.
"The work recognized today is emblematic of the ingenuity currently driving the genetics community," said an ASHG spokesperson. "These awardees are not just producing data; they are developing the tools and the frameworks that will allow the next generation of clinicians to provide more equitable, accurate, and personalized healthcare to patients worldwide."
The ASHG serves as the professional home for nearly 8,000 members, ranging from genetic counselors on the front lines of patient care to bioinformaticians working in the cloud. By celebrating these specific publications, the Society reinforces its commitment to supporting the career trajectory of researchers, acknowledging that the future of the field depends on the early, robust support of scientific talent.
Implications: The Future of Genomic Medicine
The implications of this research are far-reaching. As we move deeper into the "post-GWAS" (Genome-Wide Association Study) era, the focus of the scientific community is shifting from simple discovery to functional interpretation and predictive modeling.
Improving Clinical Accuracy
The work of Baya and Lawrence, in particular, points toward a future where "polygenic risk" is no longer a static number but a dynamic, nuanced metric that accounts for both common variation and rare, high-impact mutations. This has immediate implications for clinical genetics clinics, where clinicians often struggle to explain to patients why they possess high risk scores but do not manifest disease—or vice versa.
Artificial Intelligence as a Standard Tool
Dr. Sun’s research serves as a bellwether for the integration of AI into biological research. As data sets grow to include millions of individuals, the reliance on traditional statistical methods is being supplanted by machine learning architectures capable of identifying non-linear patterns in the genome. The ability to use variational autoencoders to refine polygenic prediction suggests that the next generation of genetic testing will be significantly more accurate than current offerings.
The Power of Functional Validation
Finally, Dr. Thomas-Charles’s work reminds the community that discovery must be followed by validation. In an era of rapid-fire genomic sequencing, the "functional bottleneck"—where we know a variant exists but do not know how it causes disease—is the primary obstacle to developing new therapies. By showing how to systematically investigate and correct a mutation, her work provides a model for how to bridge the gap between genotype and phenotype.
Conclusion
The 2026 ASHG Publication Awards serve as a vital reminder of the collaborative, iterative, and deeply human effort required to decode our biological blueprint. As these four investigators prepare to present their findings in Montréal, they carry with them the expectations and the excitement of the global scientific community.
The ASHG encourages all members of the press and the public to engage with this research, which is publicly available through the AJHG and HGG Advances platforms. For those looking to understand the future of human health, there is no better starting point than the work of these four exceptional scientists.
As registration for the 2026 Annual Meeting remains open, the Society anticipates a robust discussion surrounding these publications, underscoring the vital role that scientific publishing plays in the advancement of human health. Through these awards, ASHG continues to cultivate an environment where rigorous, innovative, and ethical research can thrive, ensuring that the promise of genomics is realized for the benefit of all.
About the Author
